Daly Richard J has made two significant stock purchases in Aquestive Therapeutics, Inc., acquiring a total of 28,025 shares. This acquisition, reported on November 12, 2026, is noteworthy as it reflects a strong confidence in the company's future prospects.

The purchases took place on November 10, 2026, with the first transaction involving 1,200 shares at $3.53 per share, followed by a larger acquisition of 26,825 shares at $3.545 each. Following these transactions, Daly now owns a total of 28,025 shares in the company.

Background

Aquestive Therapeutics, Inc. is a company engaged in the pharmaceutical preparations industry. It is incorporated in Delaware and has its business address in Warren, New Jersey. The company is publicly traded under the ticker symbol AQST.

What the Filing Says

The SEC filing indicates that the reported shares were purchased by Daly Richard J in open market transactions. The filing is identified under accession number 0001214659-26-014004.

Impact

This activity may affect investor sentiment towards Aquestive Therapeutics as it indicates a significant insider investment. Such transactions can often be viewed as a positive signal regarding the company's future performance.

What's Next

The filing does not say what happens next.

Ownership Details

Daly Richard J is identified as a director of Aquestive Therapeutics, Inc., which adds significance to his stock purchases, as directors are often seen as having a deeper understanding of the company's operations and future direction. Following the transactions, he directly owns a total of 28,025 shares of common stock in the company.

Company Information

Aquestive Therapeutics, Inc. is classified under the Standard Industrial Classification of Pharmaceutical Preparations, indicating its focus on developing and commercializing innovative drug delivery technologies. The company was formerly known as MonoSol Rx, Inc., which reflects its evolution in the pharmaceutical sector.

Filing Specifics

The SEC filing is categorized under Form 4, which is used to report the acquisition or disposition of securities by insiders. The filing was made as of November 12, 2026, and it includes details such as the transaction codes and the number of shares acquired in each transaction.

Contact Information

The business address for Aquestive Therapeutics, Inc. is located at 184 Liberty Corner Road, Suite 305, Warren, NJ, with a business phone number of 908-941-1900. This information might be useful for investors or analysts seeking further details about the company.

What the Filing Does Not Include

The filing does not provide insights into any future plans or strategies for Aquestive Therapeutics, Inc., nor does it mention any potential impacts of these stock purchases on the company's operations or stock performance.